AbbVie (ABBV) Stock Forecast & Price Target $183.08 +1.94 (+1.07%) (As of 11/27/2024 ET) Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AbbVie - Analysts' Recommendations and Stock Price Forecast (2024) How MarketBeat Calculates Price Target and Consensus Rating MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Consensus Rating Moderate BuyBased on 23 Analyst RatingsSell0Hold3Buy20 Based on 23 Wall Street analysts who have issued ratings for AbbVie in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 23 analysts, 3 have given a hold rating, 18 have given a buy rating, and 2 have given a strong buy rating for ABBV. Consensus Price Target $203.5011.15% Upside According to the 23 analysts' twelve-month price targets for AbbVie, the average price target is $203.50. The highest price target for ABBV is $225.00, while the lowest price target for ABBV is $173.00. The average price target represents a forecasted upside of 11.15% from the current price of $183.08. Get the Latest News and Ratings for ABBV and Related Stocks Enter your email address to receive the latest news and analysts' ratings for AbbVie and its competitors. Enter your email to sign up for newsletter Sign Up ABBV Analyst Ratings Over TimeTypeCurrent Forecast11/30/23 to 11/29/241 Month Ago10/31/23 to 10/30/243 Months Ago9/1/23 to 8/31/241 Year Ago11/30/22 to 11/30/23Strong Buy2 Strong Buy rating(s)1 Strong Buy rating(s)1 Strong Buy rating(s)0 Strong Buy rating(s)Buy18 Buy rating(s)14 Buy rating(s)12 Buy rating(s)8 Buy rating(s)Hold3 Hold rating(s)4 Hold rating(s)2 Hold rating(s)8 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$203.50$199.39$191.64$167.69Forecasted Upside11.15% Upside-1.07% Downside-2.38% Downside17.80% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyModerate Buy Download Our Tesla Ebook For Free (Ad)Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. ABBV Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History ABBV Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table AbbVie Stock vs. The CompetitionTypeAbbVieMedical CompaniesS&P 500Consensus Rating Score 2.96 2.80 2.50Consensus RatingModerate BuyModerate BuyModerate BuyPredicted Upside11.15% Upside24,757.91% Upside6.54% UpsideNews Sentiment RatingPositive NewsSee Recent ABBV NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails11/22/2024Leerink Partnrs5 of 5 starsD. RisingerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy11/22/2024Leerink Partners1 of 5 stars UpgradeMarket Perform ➝ Outperform$206.00+19.64%11/19/2024Wells Fargo & Company3 of 5 stars Boost TargetBuy$195.00+17.80%11/15/2024Wolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingA. HammondSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$205.00+20.85%11/13/2024JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetOverweight ➝ Overweight$210.00 ➝ $200.00+16.74%11/12/2024CitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingP. VerdultSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower TargetBuy ➝ Buy$226.00 ➝ $215.00+24.27%Top "Sleeping Giant" Crypto In The Market Now (Ad)Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future. Click here to discover our #1 crypto pick before it's too late11/12/2024BMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetOutperform ➝ Outperform$228.00 ➝ $208.00+18.74%11/12/2024Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetOverweight ➝ Overweight$231.00 ➝ $224.00+28.41%11/6/2024GuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetBuy ➝ Buy$212.00 ➝ $221.00+9.36%11/4/2024ArgusSubscribe to MarketBeat All Access for the recommendation accuracy ratingD. ToungSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy10/31/2024UBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetNeutral ➝ Neutral$195.00 ➝ $200.00-1.87%10/18/2024Bank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetNeutral ➝ Neutral$185.00 ➝ $195.00+3.45%10/17/2024Sanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingC. BreenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform$203.00+6.58%10/10/2024Truist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetBuy ➝ Buy$210.00 ➝ $215.00+10.49%10/7/2024BarclaysSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetOverweight ➝ Overweight$200.00 ➝ $212.00+9.75%10/7/2024TD CowenSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetBuy ➝ Buy$195.00 ➝ $225.00+16.22%8/30/2024William BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingM. PhippsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy8/23/2024Piper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetOverweight ➝ Overweight$196.00 ➝ $209.00+6.05%8/5/2024Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingL. ChenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.00+8.40%7/3/2024Piper Sandler CompaniesSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingOverweight ➝ Overweight$190.00 ➝ $190.00+14.48%6/5/2024HSBCSubscribe to MarketBeat All Access for the recommendation accuracy rating UpgradeHold ➝ Buy$185.00+14.08%2/5/2024Raymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetOutperform ➝ Outperform$181.00 ➝ $189.00+12.05%12/11/2023The Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating UpgradeNeutral ➝ Buy$173.00+15.89%11/9/2023Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageHold$150.00+5.60%7/12/2023Credit Suisse GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower Target$170.00 ➝ $160.00+18.02%2/10/2023Atlantic SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetNeutral$157.00 ➝ $154.00+1.83%2/10/2023SVB SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy rating UpgradeUnderperform ➝ Market Perform$135.00 ➝ $153.00+2.89%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:39 AM ET. Should I Buy AbbVie Stock? ABBV Pros and Cons Explained These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, November 21, 2024. Please send any questions or comments about these AbbVie pros and cons to contact@marketbeat.com. AbbVie Bull Case Here are some ways that investors could benefit from investing in AbbVie: AbbVie has a strong market position with a current stock price of $167.74, reflecting investor confidence and potential for growth. The company recently reported earnings of $3.00 per share, exceeding analysts' expectations, which indicates robust financial performance and effective management. AbbVie has received multiple upgrades from analysts, with Wells Fargo raising its price target to $195.00, suggesting a positive outlook and potential for stock appreciation. Institutional ownership is high, with 70.23% of shares held by institutional investors, which often indicates stability and confidence in the company's long-term prospects. AbbVie has a diverse product portfolio, including recent advancements in its pharmaceutical offerings, which can drive future revenue growth and market expansion. AbbVie Bear Case Investors should be bearish about investing in AbbVie for these reasons: The stock has experienced volatility, with a 52-week range between $137.14 and $207.32, indicating potential risks associated with price fluctuations. AbbVie has a high debt-to-equity ratio of 9.64, which may raise concerns about financial leverage and the company's ability to manage its debt effectively. Recent price target reductions from other analysts, such as Morgan Stanley lowering its target to $224.00, could signal caution among market experts regarding future performance. The company's quick ratio of 0.54 suggests potential liquidity issues, meaning it may struggle to meet short-term obligations without additional financing. AbbVie faces increasing competition in the pharmaceutical sector, which could impact its market share and profitability in the long run. ABBV Forecast - Frequently Asked Questions What is AbbVie's forecast for 2025? According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for AbbVie is $203.50, with a high forecast of $225.00 and a low forecast of $173.00. Should I buy or sell AbbVie stock right now? 23 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 3 hold ratings, 18 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ABBV shares. Does AbbVie's stock price have much upside? According to analysts, AbbVie's stock has a predicted upside of 11.15% based on their 12-month stock forecasts. Has AbbVie been upgraded by Wall Street analysts recently? Over the previous 90 days, AbbVie's stock had 3 upgrades by analysts. What analysts cover AbbVie? AbbVie has been rated by research analysts at Argus, Bank of America, Barclays, BMO Capital Markets, Citigroup, Guggenheim, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Morgan Stanley, Sanford C. Bernstein, TD Cowen, Truist Financial, UBS Group, Wells Fargo & Company, and Wolfe Research in the past 90 days. Do Wall Street analysts like AbbVie more than its competitors? Analysts like AbbVie more than other "medical" companies. The consensus rating score for AbbVie is 2.96 while the average consensus rating score for "medical" companies is 2.80. Learn more on how ABBV compares to other companies. Stock Forecasts and Research Tools Related Companies Eli Lilly and Company Stock Forecast Johnson & Johnson Stock Forecast Merck & Co., Inc. Stock Forecast Pfizer Stock Forecast Bristol-Myers Squibb Stock Forecast Zoetis Stock Forecast Royalty Pharma Stock Forecast Jazz Pharmaceuticals Stock Forecast Corcept Therapeutics Stock Forecast Perrigo Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Top secret Trump trades? (Ad)As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”Go here to see how you can start accessing these opportunities today This page (NYSE:ABBV) was last updated on 11/29/2024 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredWhy Buffett, Bezos & Congress Are Rushing Into This SectorWhy are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbbVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbbVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
